Suzhou GINFON Logistics System and Neowise Biotechnology have secured funding.
GINFON nets over $30m in Series D
Logistics automation solutions provider Suzhou GINFON Logistics System Co., Ltd has snagged over 200 million yuan ($30 million) for its Series D round funding.
The fresh round was jointly led by Shenzhen Qianhai FOF, a state-backed fund with 28.5 billion yuan ($4.4 billion) in capital commitment, as well as DHLT Investment. Existing investor Addor Capital re-upped in the round.
Proceeds from the funding round will be used for product R&D and overseas market expansion.
GINFON counts Chinese logistics-led Eastern Bell Capital as its largest external shareholder. Its services include logistics sorting, warehousing and intelligent factory automation.
GINFON’s previous investors include Israeli Infinity’s China joint fund Infinity Capital, Suzhou International Development Venture Capital Holding, Oriza Prior, among others.
Sinopharm invests in BV-backed Neowise
Baidu Venture-backed biotech startup Neowise Biotechnology has closed an undisclosed Series A round led by life science industry-focused TF Capital with participation from state-backed Sinopharm Capital.
Neowise has so far secured over 100 million yuan ($15 million) within a year since inception in September last year. Before the latest round, Neowise had completed its pre-Series A round from drug discovery platform BioMap in March this year, besides an angel round from Baidu Venture in 2020.
Neowise will use the proceeds for the R&D of gene therapy treatments and the construction of a GMP facility.
Co-founded by Dr. Songming Peng who worked at California Institute of Technology, Neowise has been focused on T-cell receptor-based gene therapies.